Neurogene Inc. (NGNE)

33.31 -0.41 (-1.22%) At close: 04:00PM EDT

Neurogene Inc.

535 W 24th Street
5th Floor
New York, NY 10011
United States
(855) 508-3568
https://www.neurogene.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 91

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Rachel L. McMinn Ph.D.	Founder, Executive Chair & CEO	676.54k	N/A	1973
Ms. Christine Mikail Cvijic J.D.	President, CFO & Corporate Secretary	623.29k	N/A	1978
Dr. Stuart Cobb Ph.D.	Chief Scientific Officer	478.81k	N/A	1970
Mr. Arvind Sreedharan	Senior Vice President of Business Operations	N/A	N/A	N/A
Ms. Donna M. Cochener-Metcalfe J.D.	Senior VP & General Counsel	N/A	N/A	1975
Dr. Effie Albanis M.D.	Senior Vice President of Early Clinical & Translational Research	N/A	N/A	N/A
Dr. Andrew E. Mulberg CPI, FAAP, M.D.	Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control	N/A	N/A	N/A
Mr. Ricardo Jimenez	Senior Vice President of Technical Operations	N/A	N/A	N/A
Dr. Julie Jordan M.D.	Chief Medical Officer	N/A	N/A	1972

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Corporate governance

Neurogene Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 4; Board: 5; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.